Care Access’ Post

The pharmaceutical industry is evolving rapidly– but how might commercial models in pharma evolve over the next years? What does it take to build a truly innovative, and analytics-driven go-to-market model to help enable healthcare professionals driving patient impact? How might industry leaders think about transforming their commercial model? Davide Piras from Bristol Myers Squibb will join McKinsey & Company experts Jan Ascher and Nils Peters to talk about the commercial model of the future on September 26th in the first webinar of our Next Generation Pharma Commercial series, hosted by Christoph A. and Wolfgang Trasischker. Do you want to join Davide and your peers to discuss the next generation pharma commercial model? Register today to mark your calendar: https://lnkd.in/ddNMV2Ke #CX #Pharma #Commercial #Digital #Webinar

On both sides of the Atlantic pharma companies are presenting cases to the courts and to national regulators that the innovation cash pipelines will be disrupted, forcing them to either cut back and delay launches or move operations to Asia Pacific or Latin America. Find out more in our newly published whitepaper featuring industry experts: ·      Christoph Glaetzer, Dipl.Kfm., Chief Global Value and Access at Johnson & Johnson Innovative Medicine ·      Ricardo Werner Marek, President Europe & Canada at Takeda ·      Andy Powrie-Smith, Executive Director, Communications & Partnerships at EFPIA - European Federation of Pharmaceutical Industries and Associations Access the full whitepaper here: https://bit.ly/3Vh46Y2

Next week I will join Nils Peters and Jan Ascher from McKinsey to discuss the commercial model of the future and reflect on my experience driving a CX transformation.  For more information and registration see the post below.  I am looking forward to the discussion!

What makes Novartis and other top pharma companies stand out in Europe? Meet the leaders driving innovation: Vasant Narasimhan (Novartis), Bill Anderson (Bayer), Paul Hudson (Sanofi), Pascal Soriot (AstraZeneca), and many more. Discover their focus areas and global strategies. Read more here: https://ow.ly/QHtZ50SJjIe #Pharma #Healthcare #HealthcareLeaders

The pharmaceutical industry is evolving rapidly– but how might commercial models in pharma evolve over the next years? What does it take to build a truly innovative, and analytics-driven go-to-market model to help enable healthcare professionals driving patient impact? How might industry leaders think about transforming their commercial model? Davide Piras from Bristol Myers Squibb will join McKinsey & Company experts Jan Ascher and Nils Peters to talk about the commercial model of the future on September 26th in the first webinar of our Next Generation Pharma Commercial series, hosted by Christoph Acher and Wolfgang Trasischker. Do you want to join Davide and your peers to discuss the next generation pharma commercial model? Register today to mark your calendar: https://lnkd.in/dBMfckiD #CX #Pharma #Commercial #Digital #Webinar

The pharmaceutical industry is evolving rapidly– but how might commercial models in pharma evolve over the next years? What does it take to build a truly innovative, and analytics-driven go-to-market model to help enable healthcare professionals driving patient impact? How might industry leaders think about transforming their commercial model? Davide Piras from Bristol Myers Squibb will join McKinsey & Company experts Jan Ascher and Nils Peters to talk about the commercial model of the future on September 26th in the first webinar of our Next Generation Pharma Commercial series, hosted by Christoph Acher and Wolfgang Trasischker. Do you want to join Davide and your peers to discuss the next generation pharma commercial model? Register today to mark your calendar: https://lnkd.in/dECz4zQh #CX #Pharma #Commercial #Digital #Webinar

At the #OPPIAnnualSummit 2023, our esteemed panel engaged in a comprehensive discussion, dissecting the challenges within the pharmaceutical industry. The crux of their conversation centred around the pivotal need for implementing measures that significantly enhance the ease of doing business. This strategic emphasis resonates with our commitment to creating a business environment that is more efficient, transparent, and supportive for the pharmaceutical sector's growth. It reflects our dedication to fostering a landscape that encourages innovation and facilitates seamless business operations. #BharatKeLiye Manoj Saxena V.Simpson E. Sanjay Sharma Rajeev Ranjan Ravi Bhola Krishna Sarma Dr. Vivek Kashyap

"I can't say enough of the discourse and community that you are building here and I really look forward to it." Hear from Arvind Balasundaram, Executive Director, Commercial Insights & Analytics at Regeneron Pharmaceuticals, as he shares his insights on CDO Vision New York and his anticipation for future endeavors with AIM Research. Click the link to discover more about his perspective! #CDOVision #AIMResearch #IndustryInsights

At Vexella Pharmaceuticals, we’re not just envisioning the future of healthcare; we’re actively shaping it. Our mission is to blend innovation, science, and elegance to revolutionize the way we approach medicine and health. We’re excited to embark on a journey where cutting-edge technology meets compassionate care. Our forward-thinking vision is rooted in a commitment to: 🔬 **Innovate:** Harnessing the power of advanced research and technology to create groundbreaking pharmaceutical solutions. 🌐 **Transform:** Pioneering new treatments that address unmet medical needs and enhance quality of life. 💡 **Inspire:** Driving a culture of excellence and sophistication that sets new standards in the industry. Join us as we pave the way for a healthier tomorrow, one breakthrough at a time. Follow our page for updates on our latest advancements, research developments, and insights into the future of healthcare. Here’s to a future where innovation meets elegance—welcome to Vexella Pharmaceuticals! #Pharmaceuticals #Innovation #Healthcare #FutureOfMedicine #VexellaPharmaceuticals

Exploring the landscape of healthcare innovation: The latest chart shows the top pharmaceutical companies by 2023 revenue, highlighting the industry's heavy hitters. With Johnson & Johnson leading at $85.16 billion, the sheer scale of the health solutions and pharmaceuticals market is clear. It's interesting to note the geographical diversity, with companies from the USA, Switzerland, France, and more making the list. What will 2024's ranking looking like? #Pharma #HealthcareInnovation #GlobalHealth #MarketTrends #Growth